I brought up this idea on WSBN discord about a week ago and I think it's starting to line up. Just as GME was a heavily shorted stock so has been KMPH with a 71% short interest as of yesterday. The company has a major catalyst with an FDA approved ADHD drug that is better than anything else out there on the market. Having ADHD I have been very interested in this...
When most of the companies are diluting their shares and insiders are selling, KemPharm, Inc. (KMPH) does the opposite. Insiders are buying and the Board of Directors authorizes a program to repurchase up to $50 million of the Company’s outstanding stock valid through December 31, 2023. It is equivalent to 18% of KemPharm’s current market capitalization. Because...
Target 1: $29 Target 2: $45 Target 3: $80 If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
$KMPH has very weak support and could retrace much lower regions in near completion of a head and shoulders formation. All signs are grossly bearish, including many large-scale sell orders having been placed in the last five days. The bigger investors have pulled the rug-- Target new entries much lower on this position if possible. Best, BDR
KemPharm, Inc., a specialized pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its candidate product includes KP415 and KP484 for the treatment of attention deficit disorder. (ADHD) For reference: ADHD has a huge market and no cures have been invented in over 10 years. If the KP415 is FDA approved (March 2), it will...
I am only playing the run up, but it has been said it is very likely FDA approves their drug. My run up target before March 2 is $15-20.